New Delhi, November 2014 –
Synergy Pharmaceuticals Inc said its experimental drug for opioid-induced constipation was found safe and effective in a mid-stage trial.
Synergy Pharmaceuticals shares were up 8 percent in premarket trading
The drug SP-333 showed statistically significant improvement in spontaneous bowel movement in the fourth week of treatment, compared with a placebo, the company said on Wednesday.
The study was designed to evaluate the effect of a once-daily oral tablet against placebo in patients who had less than three spontaneous bowel movements per week and experienced constipation-related symptoms.
Synergy said the experimental drug was found safe and well tolerated at all doses and it expects to evaluate the full dataset in the coming weeks.
The company is also developing another constipation drug called Plecanatide which is currently in a late-stage trial. Reuters
By Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru Insomnia, the persistent inability…
Illuminating Latest Advances in Migraine Diagnosis and Treatment New Delhi, December 21, 2024: In a…
New Delhi, December 20, 2024: The healthcare sector is undergoing a transformation fueled by technological…
National, December 20, 2024: DKMS just published its first Global Impact Report that outlines the organization's…
Ahmedabad, December 19, 2024: Sterling Biotech Limited, a joint venture between Perfect Day and Zydus, has…
New Delhi, December 19, 2024: Antara Senior Care, an integrated eco-system provider for lifestyle and…